The Australian Translational Medicinal Chemistry Facility (ATMCF) was established at the Monash Institute of Pharmaceutical Sciences (MIPS) to provide researchers with a medicinal chemistry facility to support early stage medicinal chemistry-led drug discovery development. MIPS is a multi-disciplinary research institute encompassing the key skills in translational aspects of drug discovery, delivery and development.
Year of establishment
Access and pricing
The ATMCF is accessible to non-commercial and commercial users, with costs dependent on the type of user and the specific arrangement (fee for service, collaboration, or another model).
ATMCF has both academic and commercial collaborators. Some examples of current projects follow:
- University of Western Australia, University of Sydney, University of Tasmania, University of Wollongong, Griffith University, Drug for Neglected Diseases initiative, University of Dundee, GSK (Tres Cantos), Swiss Tropical Health Research Institute, University of Heidelberg. This collaboration is discovering new drugs for human African trypanosomiasis ('Sleepin Sickness') and Chagas disease.
- CSIRO and investigators at Monash University. This collaboration is developing new compounds with potential antibiotic activity effective against so-called 'superbugs'.
- Walter and Eliza Hall Institute of Medical Research, CSIRO, St Vincent’s Institute of Medical Research. This collaboration is developing potent epigenetic modulators for the treatment of acute myeloid leukaemia.
- Army Malaria Institute, Griffith University, University of Melbourne. Potent antimalarial compounds are being developed and are being profiled by the pharmaceutical giant GSK.
Main contact: Jonathan Baell
Phone: +61 (0) 9903 9044
|Purpose-designed facility including two fully equipped medicinal chemistry laboratories; and an analytical support laboratory
- 14 dedicated hoods; capacity for 28 medicinal chemists
|The ATMCF can work with you to select your best high-throughput screening hits, fragment-based drug design, literature or patent lead
It can help design a mechanism-based hit, and then elaborate SAR to optimise targeted parameters, be they potency, selectivity, solubility or permeability
|Seamless and facilitated access to:
- Dedicated and extensive analytical facilities at MIPS (including NMR, MS, purification, analytical systems)
|We can optimise and move structures into clear IP space
We can interact iteratively with CDCO to assess and design-in the best drug-like properties
The ATMCF can collaborate through preclinical development, or can pass optimised compounds (or series) back to the partner as requested